However, the mechanism of ligand-receptor interaction, epigenetic regulatory model, and pharmacological feasibility of GPR115 as a therapeutic target in lung adenocarcinoma still need to be elucidated. Here, ADGRF4 is linked to lung adenocarcinoma.